Sns Will Share Ozempic to Treat Adults with Type 2 Diabetes

Observador

Dnoticias

View article

sabado.pt

View article

+2 Reposted by 2 other sources

Lean Right

Factuality

Ownership

Ozempic, used to treat type 2 diabetes, received Infarmed authorisation for participation in patients with obesity or high risk of cardiovascular disease.

echoboomer.pt

Factuality

Ownership

Infarmed authorizes co-payment for Ozempic in the National Health Service (SNS), allowing access for patients with type 2 diabetes and a BMI equal to or greater than 30 kg/m². Ozempic, a semaglutide-based medication for the treatment of type 2 diabetes, is now covered by the National Health Service for adults who are obese or at high risk of cardiovascular disease. The decision, approved by Infarmed, aims to expand access to this treatment.

famaradio.tv

Factuality

Ownership

The drug Ozempic, originally indicated for the control of type 2 diabetes, will now be subsidized by the Portuguese state for patients with obesity or high cardiovascular risk. The decision was made by the National Authority for Medicines and Health Products (Infarmed) and represents a significant expansion of access to this treatment. According to […]